NCT05727904 2026-04-03
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics, Inc.
Phase 3 Recruiting
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc.